{"id":751367,"date":"2023-04-26T09:49:04","date_gmt":"2023-04-26T13:49:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/"},"modified":"2023-04-26T09:49:04","modified_gmt":"2023-04-26T13:49:04","slug":"dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/","title":{"rendered":"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)"},"content":{"rendered":"

<\/p>\n

DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)<\/b><\/p>\n

SAN DIEGO–(BUSINESS WIRE<\/a>)–
\nDermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d or the \u201cCompany\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a physician-founded, member-focused and community-based not-for-profit health plan in New York. The contract, which is in addition to a favorable coverage policy that became effective April 15, 2023, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the approximately 400,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV).<\/p>\n

\n\u201cWe are eager to bolster our relationship with this key payer in New York and further reduce barriers to access with our test now available as an in-network benefit,\u201d said Chris Murphy, senior director of payer access, DermTech. \u201cThe DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. After reviewing our portfolio of clinical and health economic data, payers are recognizing the value of our test and resulting benefits to their membership, network providers and health plans.\u201d<\/p>\n

\nDermTech\u2019s total covered lives in the U.S. are approximately 126 million, which includes 68 million for Medicare\/Medicare Advantage and 58 million for commercial and governmental payers.<\/p>\n

About The DermTech Melanoma Test<\/b><\/p>\n

\nDermTech originally marketed its foundational assay under the name Pigmented Lesion Assay (PLA). The PLA assesses pigmented skin lesions, moles or dark skin spots for melanoma. In particular, the PLA detects expression of the LINC00518 (LINC) and preferentially expressed antigen in melanoma (PRAME) genes using reverse transcription-polymerase chain reaction (RT-PCR). The Company introduced its second-generation test in 2021 as an add-on assay to PLA, which is designed to identify the presence of mutations in TERT gene promoter region using DNA sequencing. The Company has since branded its PLA and TERT add-on-assay as the DermTech Melanoma Test (DMT). The DMT may be ordered with or without the add-on test for TERT. Positive results for LINC, PRAME or TERT correlate with a lesion at higher risk for melanoma. If none of the biomarkers are detected, this result indicates a greater than 99% probability that the mole being tested is not melanoma.<\/p>\n

About DermTech<\/b><\/p>\n

\nDermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech\u2019s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers\u2122. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

This press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d “outlook,” \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech\u2019s products and the market opportunity for these products, DermTech\u2019s positioning and potential revenue growth, financial outlook and future financial performance, ability to maintain or improve its operating efficiency and reduce operating expenses, implications and interpretations of any study results, expectations regarding agreements with or reimbursement or cash collection patterns from Medicare or commercial payers and related billing practices or number of covered lives, and DermTech\u2019s ability to expand its product offerings and develop pipeline products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech\u2019s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech\u2019s tests; (4) the reimbursement of DermTech\u2019s tests by Medicare and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech\u2019s products; (6) DermTech\u2019s ability to grow, manage growth and retain its key employees and maintain or improve its operating efficiency and reduce operating expenses; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech\u2019s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and\/or competitive factors; and (9) other risks and uncertainties included in the \u201cRisk Factors\u201d section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the \u201cSEC\u201d), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.<\/i><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230426005152\/en\/<\/a><\/span><\/p>\n

\nSteve Kunszabo
\n
DermTech
\n
(858) 291-1647
\n
steve.kunszabo@dermtech.com<\/a><\/p>\n

KEYWORDS:<\/b> California New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Biometrics Genetics General Health Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) SAN DIEGO–(BUSINESS WIRE)– DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d or the \u201cCompany\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a physician-founded, member-focused and community-based not-for-profit health plan in New York. The contract, which is in addition to a favorable coverage policy that became effective April 15, 2023, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the approximately 400,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV). \u201cWe are eager to bolster … <\/p>\n

Continue reading “DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751367","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nDermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) SAN DIEGO–(BUSINESS WIRE)– DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d or the \u201cCompany\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a physician-founded, member-focused and community-based not-for-profit health plan in New York. The contract, which is in addition to a favorable coverage policy that became effective April 15, 2023, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the approximately 400,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV). \u201cWe are eager to bolster … Continue reading "DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T13:49:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)\",\"datePublished\":\"2023-04-26T13:49:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/\"},\"wordCount\":999,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/\",\"name\":\"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-04-26T13:49:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/","og_locale":"en_US","og_type":"article","og_title":"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) - Market Newsdesk","og_description":"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) SAN DIEGO–(BUSINESS WIRE)– DermTech, Inc. (NASDAQ: DMTK) (\u201cDermTech\u201d or the \u201cCompany\u201d), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a physician-founded, member-focused and community-based not-for-profit health plan in New York. The contract, which is in addition to a favorable coverage policy that became effective April 15, 2023, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the approximately 400,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV). \u201cWe are eager to bolster … Continue reading \"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T13:49:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)","datePublished":"2023-04-26T13:49:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/"},"wordCount":999,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/","name":"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-04-26T13:49:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230426005152r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dermtech-announces-contract-with-new-york-health-plan-for-the-foundational-assay-of-its-dermtech-melanoma-test-dmt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751367"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751367\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}